March 12, 2021

Novavax Says COVID-19 Vaccine Has 89.7% Efficacy-Devex

Novavax’s COVID-19 vaccine has an overall efficacy of 89.7%, according to final results of its phase 3 efficacy trial in the United Kingdom. It has a 96.4% efficacy against the original strain of the COVID-19 virus, but 86.3% when accounting for the B.1.1.7/501Y.V1 variant first found in the United Kingdom. Meanwhile, the vaccine has shown 48.6% efficacy in South Africa, where the B1.351 variant is dominant. Efficacy is higher at 55.4% for HIV-negative individuals. Devex, 03/12/2021